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Abstract
Most inborn errors of metabolism (IEM) are recessive, genetically transmitted diseases and are classified into 3 main
groups according to their mechanisms: cellular intoxication, energy deficiency, and defects of complex molecules.
They can be associated with endocrine manifestations, which may be complications from a previously diagnosed
IEM of childhood onset. More rarely, endocrinopathies can signal an IEM in adulthood, which should be suspected
when an endocrine disorder is associated with multisystemic involvement (neurological, muscular, hepatic features,
etc.). IEM can affect all glands, but diabetes mellitus, thyroid dysfunction and hypogonadism are the most frequent
disorders. A single IEM can present with multiple endocrine dysfunctions, especially those involving energy
deficiency (respiratory chain defects), and metal (hemochromatosis) and storage disorders (cystinosis). Non-
autoimmune diabetes mellitus, thyroid dysfunction and/or goiter and sometimes hypoparathyroidism should steer
the diagnosis towards a respiratory chain defect. Hypogonadotropic hypogonadism is frequent in
haemochromatosis (often associated with diabetes), whereas primary hypogonadism is reported in Alström disease
and cystinosis (both associated with diabetes, the latter also with thyroid dysfunction) and galactosemia.
Hypogonadism is also frequent in X-linked adrenoleukodystrophy (with adrenal failure), congenital disorders of
glycosylation, and Fabry and glycogen storage diseases (along with thyroid dysfunction in the first 3 and diabetes
in the last). This is a new and growing field and is not yet very well recognized in adulthood despite its
consequences on growth, bone metabolism and fertility. For this reason, physicians managing adult patients
should be aware of these diagnoses.
Keywords: Inborn errors of metabolism, endocrine dysfunction, hypogonadism, diabetes mellitus, thyroid dysfunc-
tion, hypopituitarism, adrenal failure, hypoparathyroidism
Introduction
Inborn errors of metabolism (IEM) are rare genetic dis-
eases, which usually have a recessive mode of inheri-
tance. They are classified into 3 main groups according
to their mechanisms: cellular intoxication, energy defi-
ciency, and degradation or synthesis defects of complex
molecules [1]. This is a new and growing field in adult-
hood and is not yet very well known.
Endocrine manifestations can be a complication of a
previously diagnosed IEM. More rarely they may signal
t h ep r e s e n c eo fan e wI E M ,m o s t l yt h o s ei n v o l v i n g
glucose metabolism and presenting with hypoglycaemia
(see the related article for review). Nevertheless all types
of endocrine disorders have been described in IEM
(Table 1), and the endocrinologist should be aware of
them when an endocrine disorder is associated with
multisystem involvement, for example with neurological,
muscular and/or hepatic features.
Many endocrine manifestations in IEM might go
unrecognized, especially with regard to subclinical dys-
functions. Otherwise, the long-term consequences of
IEM on growth, bone metabolism and fertility have not
been prospectively investigated.
When fertility is maintained, all pregnancies in
patients with a previously diagnosed IEM should be
carefully planned and monitored, especially those with
dietary management, such as with phenylketonuria.
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cially hypothyroidism, is recommended in most IEM, as
is investigation for gestational diabetes. Genetic counsel-
ing should be provided, even though most IEMs, except
for mitochondrial diseases, are inherited in an autosomal
recessive manner. Prenatal testing for high-risk pregnan-
cies may be discussed if the disease-causing mutations
in the family are known.
The aim of this review is to identify the main IEMs in
adults that can be revealed or complicated by an endo-
crine disorder other than hypoglycaemia.
Why endocrine disorders in IEM?
Hormones play an essential role in the coordination of
complex functions such as growth, reproduction, meta-
bolism and energy homeostasis. Hormonal disturbance
could contribute to IEM consequences in adulthood.
The endocrine system also has paracrine and autocrine
functions and is intimately connected with nervous and
immune networks by neuromediators and cytokines.
Hormones are classified according to three types: 1)
peptide hormones (insulin, parathyroid hormone, pitui-
tary hormones), 2) hormones synthesized from a single
amino-acid (catecholamines, thyroid hormones), all
derived from tyrosine; and 3) steroid hormones (adrenal
and gonadal hormones), all synthesized from cholesterol.
Peptide hormones and catecholamines are hydrosoluble
and act through different kinds of membrane receptors,
the activation of which requires energy. In contrast, ster-
oid and thyroid hormones are liposoluble, circulate
bound to specific transporter proteins and are able to
cross the cell membrane before acting through cytoplas-
mic or nuclear receptors. On the whole, the pathophy-
siology of endocrine dysfunctions in IEM remains
poorly understood. IEM can affect all glands, both in
their structure and their secretion, but diabetes mellitus,
thyroid dysfunction and hypogonadism are the most
commonly associated disorders.
The three mechanisms known to interfere with hor-
mone metabolism may act by 1) ruining the gland struc-
ture through progressive accumulation of toxic
substances like metal [iron in haemochromatosis (> 1/
1000, ORPHA139498)], cystine [cystinosis (< 1-9/
1000000, ORPHA213)] or complex molecules [sphingo-
lipids, glycogen, galactose, abnormal glycosylated com-
pounds, or very long chain fatty acids (VLCFA)]; 2)
directly or indirectly disturbing the energy availability
required for hormone synthesis (as in respiratory chain
disorders) or hormone release (as in underproduction of
insulin-causing diabetes in Rogers syndrome (< 1-9/
1000000, ORPHA49827); or 3) preventing correct hor-
mone biosynthesis in organelles or hormone transport
into the target organ, as in cerebral monocarboxylate 8
(MCT8) defect, in which the thyroid hormone cannot
cross the blood brain barrier.
Intoxication diseases: Endocrine consequences mainly in
haemochromatosis and galactosemia (< 1-9/100000,
ORPHA352) (Table 1)
No obvious endocrine consequences have been
described so far in aminoacidopathies, urea cycle disor-
ders or organic acidurias.
In haemochromatosis the pancreas and gonads are the
most frequently affected glands with an accumulation of
iron. Clinical manifestations can be prevented or
improved through treatment. In contrast, hypogonadism
in female patients with galactosemia, the mechanism of
which is not known, is a unique endocrine complication.
It is nearly constant in most cases despite early prospec-
tive treatment. Diagnosis is easy and relies on blood and
urine analyses.
Disorders of energy metabolism: Frequent multi-
endocrine involvement (Table 1)
Respiratory chain defects and glycogen storage diseases
(GSD) are associated with the highest number of endo-
crine anomalies. Energy deficient production in the for-
mer (in which all glands can be involved) and glycogen
deposits and secondary glycosylation disturbances in the
latter (in which only the pancreas and ovaries are
affected) are the most probable (but not demonstrated)
mechanisms involved in these disorders.
Diagnosis is difficult and relies on function tests; enzy-
matic analyses requiring biopsies or cell culture; and
molecular analyses.
Organelle disorders involving the synthesis or
degradation of complex molecules: Main endocrine
consequences on liposoluble hormones (Table 1)
Fabry disease (< 1-9/100000, ORPHA324) and cystinosis
(< 1-9/1000000, ORPHA213), both lysosomal, X-linked
adrenoleukodystrophy (X-ALD) (1-9/100000,
ORPHA43), peroxisomal, and congenital disorders of
glycosylation (CDG) (< 1/1000000, ORPHA137), both
related to endoplasmic reticulum and Golgi dysfunction,
are the most frequent IEM responsible for endocrine
manifestations in this group (Table 1). In cystinosis,
lysosomal cystine accumulation may cause diabetes,
hypogonadism, hypothyroidism and short stature with-
out a clear mechanism. These complications are only
partially prevented or improved with cysteamine treat-
ment. In Fabry disease, subclinical dysthyroidism is fre-
quent and seems to respond to enzyme therapy. Adrenal
failure is an almost constant finding in X-ALD and is
caused by defective catabolism resulting in VLCFA
accumulation, which interferes with steroid hormone
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Page 2 of 19Table 1 Endocrine manifestations of inborn errors of metabolism in adults
IEM
General classification
IEM associated with endocrine
manifestations and most important
mechanism
ENDOCRINE MANIFESTATIONS
Diabetes Dysthyroidism Hypopara-
thyroidism
Adrenal
failure
Hypogonadism Hypopituitarism
INTOXICATION
Metal intoxication
Haemochromatosis
Aceruleoplasminemia
Wilson’s
Sugar intolerances
Galactosaemia
Most organic acidurias
Haemochromatosis
Iron storage
Diabetes
10%
<1 % <1 % <1 % Hypogonadotropic
5-10%
< 1% except for acquired
iron overload and
hypogonadism
Aceruloplasminemia
Iron storage
Diabetes rare
Wilson’s disease
Copper storage
Hypoparathyroidism
rare
Galactosaemia
Galactose metabolites
Hypergonadotropic
in female
Short stature
Organic aciduria
Organic acids
Possible
ketoacidosis
pancreatitis
ENERGY DEFECT
Mitochondrial disorders:
Respiratory chain disorders
Fatty acid oxidation defects
Respiratory chain defect
Deficient energy production
Diabetes All types of
thyroid
dysfunction
Hypoparathyroidism
rare
Subclinical
adrenal
failure
Hypogonadotropic Hypopituitarism
Short stature
30 to 50%
LCHAD
Deficient energy production
Hypo-
parathyroidism
Cytoplasmic energy defects
Disorders of glycogen
metabolism
Glycogenosis
Glycogen storage
(type I, III)
Diabetes Thyroid
dysfunction
(type Ib)
Mixed or
undetemined
PCOS (type I)
COMPLEX MOLECULES
Peroxisomal disorders
X-linked adreno-leukodystrophy
Perrault syndrome
VLCFA accumulation
Adrenal
failure
Mixed or
undetemined
(mainly
hypergonadotropic)
Lysosomal disorders Fabry disease
Globoside storage in lysosomes
Subclinical
hypothyroidism
Subclinical
adrenal
failure
Infertility
Cystinosis
Cystine in lysosomes
Diabetes Hypothyroidism
75%
Hypergonadotropic Short stature
30 to 50%
Disorders of intracellular
trafficking and processing such
as
Congenital disorders of
glycosylation
Inborn errors of cholesterol
synthesis.
CDG I
Abnormal glycosylated proteins
Congenital
hypothyroidism
Mixed or
undetermined
mainly
hypergonadotropic
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9Table 1 Endocrine manifestations of inborn errors of metabolism in adults (Continued)
Multisystemic triglyceride storage
disease
Triglyceride storage in endoplasmic
reticulum
Thyroid
dystrophy
Type 1 hyperoxaluria
Oxalate
Hypothyroidism Advanced bone
age
Type B Niemann-Pick disease
Sphingolipid storage in lysosomes
Partial
rare
Short stature
TRANSPORTER
DEFECT
Rogers syndrome:
Thiamine-sensitive megaloblastic
anaemia
Defective ATP production in ß cells
Diabetes
MCT8 deficiency
Defective T3 transport in neurons
High blood T3
Alström syndrome Diabetes Hypothyroidism Hyper- and
hypogonadotropic
(men)
PCOS in women
Rare hypopituitarism
Initial advanced bone age
Selenoprotein deficiency disorder Low T3-High T4 Oligospermia Short stature
CDG: congenital disorders of glycosylation; IEM: inborn errors of metabolism; LCHAD: long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency; MCT8: Monocarboxylate transporter; PCOS: polycystic ovary syndrome;
T3: triiodothyronine; T4: thyroxine; VLCFA: Very long chain fatty acids.
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9synthesis. Hypogonadism may also be observed in X-
ALD and Perrault syndrome (< 1/1000000,
ORPHA2855), in which a defect in peroxisomal VLCFA
oxidation has been recently described. Abnormal glyco-
sylation of a variety of proteins involved in hormone
metabolism, such as transporters, receptors, and hor-
mone processing could be the cause of hypogonadism
and hypothyroidism in CDG syndromes.
This first section has aimed at providing an overview
of the main endocrinopathies associated with a given
IEM, summarized in Table 1. The next sections will aim
to clarify which IEMs can be associated with a given
endocrinological disturbance, such as diabetes (Table 2),
dysthyroidism (Table 3) and hypogonadism (Table 4).
Diabetes
Several IEM can be associated with diabetes mellitus
(Table 2). The main mechanisms of diabetes in IEM
involve either defects of insulin secretion or insulin
resistance, which might be promoted by liver or muscle
involvement and estrogen deficiency [1]. The insulinope-
nic forms of diabetes are not associated with autoim-
mune features, and ketoacidosis might be the presenting
sign, especially in haemochromatosis and mitochondrial
diseases. In addition, the phenotype of some disorders
might vary from hypo- to hyperglycemia according to
age or genotype [defects in biotinidase (1-9/100000,
ORPHA79241), organic acidurias, ABCC8 mutations].
Diabetes likely to signal an IEM: Trend towards
insulinopenia (Table 2)
Hereditary haemochromatosis is the most frequent
IEM in adults [2]. The phenotype varies according to
the penetrance of the mutations of the HFE 1 gene,
which affects 0.3% of the general population. The preva-
lence of diabetes in haemochromatosis, usually 20% to
50%, has decreased to 5% to 10% due to earlier genetic
screening. In contrast, the prevalence of haemochroma-
tosis in the diabetic population is 1.3%. Increased duo-
denal iron absorption due to an impairment of hepcidin
synthesis accounts for the development of cellular iron
excess in most cases of haemochromatosis. Genes other
than HFE1 may account for hereditary forms of haemo-
chromatosis. The form caused by mutations of the
hemojuvelin gene has a juvenile onset and is often
revealed by cardiopathy and hypogonadism. Non-trans-
ferrin-bound iron plays an important role in cellular
iron damage through an increase in oxidative stress.
First, liver iron overload promotes the occurrence of
insulin-resistant diabetes [3]. The pancreas ß cells may
then be progressively destroyed, leading to C-peptide
negative diabetes and requiring insulin therapy besides
iron depletion.
Aceruloplasminemia (< 1-9/1000000, ORPHA48818)
is characterized by the accumulation of iron in the liver,
islets of Langerhans and the brain, related to decreased
cellular iron egress, in contrast with most other types of
iron overload [4]. The treatment with phlebotomies and
iron chelation is efficient in preventing both neurologi-
cal involvement and diabetes [5]. Annual glucose toler-
ance testing, starting at age 15 years, has been
recommended.
Mitochondrial diabetes makes up 0.06 to 2.8% of
cases of type 2 diabetes and should be suspected in
young, lean patients with non-autoimmune diabetes and
neurosensory or muscular involvement [6-9]. It is
maternally inherited and may be associated with multi-
ple endocrine dysfunctions. Diabetes can progressively
evolve towards insulin requirement, but inaugural ketoa-
cidosis has also been reported. The need for insulin
treatment is common, but the diabetes is usually easy to
control. Proteinuria and renal insufficiency occur more
frequently than usual in diabetes [10]. This form of dia-
betes is explained by insulinopenia, which is either
related to the destruction of ß cells or to a defect of
insulin secretion as a consequence of the energy defect.
In the first case, the production of ATP through the gly-
colysis pathway, too low to ensure normal cell function,
leads to cell death, as confirmed histologically by a
reduction in the number of ß cells [11,12]. It also pre-
vents closure of the potassium channels, inducing a
defect in insulin secretion [13-15]. Insulin sensitivity in
skeletal muscle is also decreased [15].
The most frequent genetic abnormality is the single
mutation A3243G (mitochondrial DNA), particularly in
MIDD (< 1-9/1000000, ORPHA225) and MELAS (< 1-5/
10000, ORPHA550) syndromes. Heteroplasmy plays a cen-
tral role in the phenotypic expression of the same muta-
tion, and a higher level has been found in mitochondrial
diabetes in the endocrine pancreatic ß cells than in the
exocrine cells and blood leukocytes [16]. Correction of the
consequences of mitochondrial 3243A > G mutation by
tRNA import into mitochondria has been attempted, rais-
ing new hopes in the treatment of the disease [17].
Complex rearrangements are more often encountered
in Kearns-Sayre syndrome (< 1-9/100000, ORPHA480),
isolated diabetes and Wolfram syndrome (< 1-9/
1000000, ORPHA3463) [18]. Wolfram syndrome, also
called DIDMOAD (Diabetes Insipidus, Diabetes Melli-
tus, Optic Atrophy, Deafness) may also be linked to an
autosomal recessive mutation of the WFS1 gene encod-
ing Wolframin (nuclear DNA) [19]. In this case, diabetes
appears earlier in males than in females, with low
plasma insulin concentration and increased proinsulin/
insulin ratio, which in the long-term may lead to insulin
deficiency [20].
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Page 5 of 19Table 2 Main causes of diabetes mellitus related to inborn errors of metabolism (IEM)
DISEASES GENERAL CONTEXT ENDOCRINE DYSFUNCTION:
DIABETES
IEM DIAGNOSIS TREATMENT
Diabetes likely to
signal an IEM: rather
insulinopaenic
Hereditary
haemochromatosis
Melanodermy
Hepatomegaly
Rheumatologic involvement
Early heart involvement in juvenile
forms
Complication: cirrhosis and
hepatocarcinoma
All types of Diabetes 10%
- First insulin resistance
- Then insulinopenia
Possible inaugural ketoacidosis
Hypogonadotropic
hypogonadism
Transferrin saturation > 45%,
serum ferritin > 200 (F), 300 (M)
μg/l
HFE gene mutation: HFE-1: 97%
in Caucasians
HFE-2: hemojuveline and
hepcidin
HFE-3: transferrin receptor
HFE-4: ferroportin (autosomal
dominant)
Others
Insulin-sensitiser
Insulin therapy
Phlebotomy
Hereditary
acoeruloplasminemia
Adult-onset neurological and
psychiatric disease (chorea,
cerebellar ataxia, retinal
degeneration)
Differential diagnosis of high blood
ferritin
- Normal transferrin saturation
Dysmetabolic hepatosiderosis
Inherited atransferrinaemia,
Gaucher’s disease
-Increased transferrin saturation
Multiple blood transfusions
(thalassaemia)
Diabetes mellitus due to iron
overload,
Anaemia
High serum ferritin
Absence of serum
coeruloplasmin
Coeruloplasmin gene mutations
Insulin therapy
Iron chelation
Mitochondrial
diseases
(respiratory chain
defects)
MIDD
MELAS
Kearns-Sayre
syndrome
DIDMOAD
Deafness, pigmentary retinitis,
Neuromuscular symptoms
Kidney insufficiency
Maternal inheritance
Non-autoimmune diabetes in a
lean patient > 30 years, possible
inaugural ketoacidosis
Thyroid dysfunction
More rarely hypoparathyroidism,
adrenal insufficiency,
hypogonadism, hypopituitarism
Possible diabetes insipidus
Blood lactates/pyruvate ratio
Blood ßOHbutyrate/acetoacetate
ratio
CSF lactates- urinary organic
acids
Plasma amino acids: high
alanine and proline
Muscle biopsy
Mitochondrial DNA study
Mitochondrial DNA or WFS1
gene study
Insulin therapy
Coenzyme Q10
Channelopathies
(ABCC8 gene)
Sometimes childhood fasting
hypoglycaemia
Early adult-onset non-
autoimmune diabetes
Heterozygous mutation in
ABCC8 gene (autosomal
dominant)
Sulfonylurea/
insulin
Diabetes
complicating a
previously diagnosed
IEM
Glycogen storage
disease
I and III
Hepatomegaly (I and III)
Mild muscular symptoms (Type III)
Childhood fasting hypoglycaemia
Progression to adult fasting
hypoglycaemia with
postprandial hyperglycaemia
Fasting hypoglycaemia
Lactic acidosis (preprandial I,
postprandial III)
Glc-6-P (I) and debranching
enzyme (III) genes mutation
Alpha-
glucosidase
inhibitor and/or
Insulin-sensitiser
Alström syndrome Short stature
Renal failure
Dilated myocardiopathy
Blindness, deafness
Early insulin-resistant diabetes
mellitus (82%)
Childhood obesity
Hypogonadism
Hypothyroidism
Major Hypertriglyceridaemia
HypoHDLemia
ALMS I gene mutation
Insulin-sensitiser
Insulin therapy
Cystinosis early-onset Fanconi syndrome with
polyuria and hypophosphatemic
rickets
then complicated by blindness
myopathy, central nervous system
impairment- renal insufficiency.
Diabetes mellitus 25%
Hypothyroidism 75%
Hypogonadism 74% (males)
Delayed puberty
Growth retardation
Renal tubular Fanconi syndrome
(hypokalemia, acidosis,
dehydration, kidney loss of
phosphate, glucose and amino
acids)High leukocyte cystine
Cystinosin (CTNS) gene mutatin
Electrolyte/
vitamin
supplementation
Indomethacin
Cysteamine
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Page 6 of 19Monogenic form of diabetes by ABCC8 gene muta-
tions: Activating heterozygous mutations in KCNJ11
and ABCC8 genes, which form the ATP-sensitive K+
channel, usually causes transient or permanent neonatal
diabetes. Nevertheless, the occurrence of diabetes in
young adults has recently been reported and is related
to a heterozygous activating mutation of the ABCC8
gene encoding the sulphonylurea receptor 1 (SUR1)
[21]. The clinical phenotype of these patients is hetero-
geneous, either sensitive to sulfonylurea or requiring
insulin. It appears to be modified by variable sensitivity
to insulin according to hyperinsulinemic euglycemic
clamp studies [22]. The phenotype associated with
dominant inactivating (loss-of-function) ABCC8/KCNJ11
mutations, known to range from asymptomatic macro-
somia to persistent hyperinsulinemic hypoglycemia in
childhood, may also be an important cause of inherited
early-onset diabetes mellitus in adults [23].
In conclusion, diabetes that is likely to reveal an IEM
in adults is mainly related to hereditary haemochroma-
tosis in association with hypogonadism, or to mitochon-
drial diabetes in association with multiple
endocrinopathies. ABCC8/KCNJ11 mutations have been
more recently identified in early-onset non-type 1 dia-
betes. The prognosis of hereditary haemochromatosis
has improved due to earlier genetic screening.
Diabetes complicating a previously diagnosed IEM (Table
2)
Glycogen storage disease (GSD or glycogenosis) is the
result of defects in the processing of glycogen synthesis
or breakdown within muscles, liver, and other cell types.
GSD is classified according to the type of genetically
defective enzymes and induces hepatomegaly, hypogly-
cemia and/or muscular symptoms. GSD, especially types
I (ORPHA364) and III (ORPHA366), can be compli-
cated by diabetes in the later stage [24]. Type I GSD is
initially associated with severe fasting hypoglycaemia.
Postprandial hyperglycemia (sometimes in contrast with
fasting hypoglycaemia) can occur in adulthood [25].
This fact could be explained either by recurrent pan-
creatitis episodes linked to hypertriglyceridemia, thus
leading to insulin secretion impairment, or to an
adaptive mechanism of the glucose receptor, GLUT2,
for reducing the secretion of insulin. Diabetes is also
promoted by insulin resistance related to liver and/or
muscle dysfunction [26,27]. Gene therapy is under
evaluation.
Alström syndrome: Alström syndrome (< 1-9/
1000000, ORPHA64) is characterized by a wide-ranging
spectrum of phenotypes.
.In a series of 182 patients,
hyperinsulinemia developed in early childhood (92%)
and progressed to type 2 diabetes mellitus in 82% of
those older than 16 years. Hypertriglyceridemia (54%)
precipitated pancreatitis in 8 patients [28]. An oral glu-
cose tolerance test should be considered annually, since
fasting blood glucose is often normal at diagnosis. If
blood glucose control is poor on insulin therapy, esca-
lating doses may not be effective [29]. Unlike insulin-
resistance indices, b-cell function indices show a signifi-
cant reduction with age [30]. Mutations of the ALMS1
gene cause dysfunction of the primary cilium, an orga-
nelle involved in cell sensing, as in another model of
genetic obesity, the Bardet-Biedl syndrome. The higher
frequency of diabetes in Alström syndrome is explained
b yt h es p e c i f i cr o l eo fALMS1 in b-cell function and/or
peripheral insulin signaling pathways, in parallel with
adipogenesis impairment [31].
Cystinosis is a lysosomal disease, which induces an
intracellular accumulation of cystine due to transporta-
tion impairment. It presents as a multisystemic injury
dominated by renal manifestations. Twenty-four percent
of a cohort of 100 patients had diabetes, with a quarter
of those needing insulin therapy, in addition to other
endocrinopathies such as hypothyroidism and hypogo-
nadism [32-34]. The pathophysiology of diabetes melli-
tus is mainly due to decreased insulin secretion
associated with pancreatic fibrosis. Microarray studies
have shown that some of the differentially regulated
genes in cystinosis were involved in mitochondrial dys-
function, endoplasmic reticulum and oxidative stress, as
well as immune function [35].
Thiamine-sensitive megaloblastic anemia (Rogers
syndrome) [36] is characterized by diabetes and deaf-
ness due to a lack of thiamine in pancreatic islet and
cochlear cells. It is caused by a defect in the active
Table 2 Main causes of diabetes mellitus related to inborn errors of metabolism (IEM) (Continued)
Thiamine-responsive
megaloblastic
anaemia syndrome
Megaloblastic anaemia
Progressive perception deafness in
infancy
Thiamine-sensitive diabetes
mellitus, frequently insulin-
dependent; possible ketoacidosis
SLC19A2 gene inactivation
(thiamine transporter THTR1
gene)
B1Vitamin
Insulin therapy
Organic aciduria Cognitive disorders Transient hyperglycaemic
ketoacidosis
Urinary organic acids Insulin therapy
The other genetic types of diabetes have been ruled out: Down’s, Klinefelter, Turner, Friedreich, Huntington, Laurence-Moon-Biedl, Prader-Willi, porphyria, Toni-
Debre-Fanconi, cystic fibrosis, Maturity Onset Diabetes of the Young (MODY) and neonatal diabetes. Definitions: F: female; M: male; MIDD: Maternal Inherited
Diabetes Deafness; MELAS: Myopathy, Encephalopathy, Lactic Acidosis, Stroke; DIDMOAD: Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness or
Wolfram syndrome; Kearns-Sayre syndrome: Starting before 20 years with progressive ophthalmoplegia, retinitis pigmentosa, cardiac conduction disorders and
multisystemic injury. Thiamine-responsive megaloblastic anaemia syndrome or Rogers syndrome. CSF: cerebrospinal fluid. G-6-P: Glucose-6-phosphatase.
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Page 7 of 19Table 3 Main inborn errors of metabolism associated with thyroid dysfunction
DISEASES CLINICAL
MANIFESTATIONS
ENDOCRINE DYSFUNCTION: DYSTHYRODISM DIAGNOSIS TREATMENT
Energy defect
Mitochondrial
disease
Involving seemingly
unrelated organs
Maternal inheritance
Deafness, retinitis
pigmentosa
Short stature,
Neuromuscular
symptoms
Kidney insufficiency
Goiter, hypo-/hyperthyroidism, thyrotropic
insufficiency
Non-autoimmune diabetes in a lean patient > 30
years
More rarely hypoparathyroidism, adrenal
insufficiency, hypogonadism, hypopituitarism
Blood lactate/pyruvate
ratio (high)
Blood ßOH butyrate/
acetoacetate ratio: high
CSF lactate (high)
Urinary organic acids
Plasma amino acids:
high alanine & proline
Muscle biopsy
Mitochondrial DNA
study
Discuss coenzyme Q10
Glycogenosis Liver involvement
Infections in type Ib
Growth failure
Renal complications
in adulthood
Increased prevalence of autoimmune
hypothyroidism in type I b
Children: fasting ketotic hypoglycaemia
Adults:
I, III types: polycystic ovary syndrome, diabetes,
osteoporosis
VI, IX types: spontaneous recovering delayed
puberty
Fasting hypoglycaemia
Hyper-lipaemia,
-uricaemia
Hyperlactataemia:
- fasting predominant:
type I
- postprandial
predominant: type III, VI,
IX
Leukocytes DNA gene
mutation
Frequent food intake
Uncooked cornstarch
Low carbohydrate
glycaemic index
Night enteral feeding
G-CSF in Ib type,
Allopurinol
Avoid oestroprogestative
pills
Degradation and
synthesis of
complex molecules
Fabry disease Acroparesthesia
Angiokeratoma
Stroke at young age
Renal, heart and eye
involvement in boys
Subclinical hypothyroidism
Isolated case report of subclinical adrenal
insufficiency and hypoparathyroidism
Infertility, osteoporosis
Alpha-galactosidase A
in males
Leukocytes GLA gene
mutation in females
(X-linked)
Substitutive recombinant
enzyme therapy
Cystinosis 3 forms: infantile,
juvenile, ophthalmic
(adulthood)
Liver and muscle
involvement
Evolution to end
stage renal disease
Hypothyroidism > 50%
Hypergonadotropic hypogonadism (in males)
Insulin-dependant diabetes
Growth failure
Gluco-phospho-aminic
diabetes
Hypokalaemia, acidosis,
Leukocyte cystin
measurement
Leukocytes CTNS gene
mutation
Electrolyte
supplementation
Vitamins
Indomethacin
Cysteamine
Type 1
hyperoxaluria
Recurrent oxalic
lithiasis leading to
end stage renal
disease
Bone, eye, heart
involvement
Hypothyroidism
- often severe
- sometimes signalling disease
Hyperoxaluria
Hyperglycoluria
Alanine-glyoxylate-
aminotransferase
measurement on liver
biopsy
Leukocytes AGXT gene
mutation
Abundant hydration
Urine alkalinisation
Pyridoxine phosphate
Kidney and liver
transplantation
Neutral lipid
storage disease
Ichtiosis or Chanarin-
Dorfman syndrome
or myopathy/
cardiomyopathy
Hepatomegaly
Central nervous
system involvement
Nodular dystrophy of the thyroid
(clear cells follicular adenoma)
Normal lipid levels
CPK sometimes
moderately increased
Accumulation of
triglycerides
- in leukocytes (Jordan’s
abnormality)
- in muscle, skin
fibroblasts, liver
(steatosis)
Leukocytes or
fibroblasts ABHD5 or
PNPLA2 gene mutation
No effective treatment
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THTR1), which leads to ß cell apoptosis and insulin
secretion impairment. In contrast with neurosensory
disorders, anemia and diabetes improve with pharmaco-
logical doses of oral thiamine and may lead to insulin
discontinuation. Poor blood glucose control however
reoccurs most of the time during adolescence, thus
requiring resumption of insulin therapy [37,38].
Organic Aciduria: Propionic (< 1-9/100000,
ORPHA35), methylmalonic (< 1/1000000, ORPHA26)
and isovaleric acidemias (1-9/100000, ORPHA33) are
sometimes discovered during infancy through the pre-
sence of hyperglycemic ketoacidosis, which may suggest
diabetes, particularly during pancreatitis, one of the
complications of the disease [39,40]. Diabetes has never
been reported to be a presenting manifestation of
organic aciduria in adulthood, but should be kept in
mind since mitochondrial dysfunction has been reported
to be associated with it [41].
Finally, diabetes may also complicate a previously
diagnosed IEM, particularly those inducing impairment
of the degradation or synthesis of complex molecules. In
this group, hypothyroidism or hypogonadism are fre-
quently associated endocrine disorders.
In conclusion, diabetes, mainly linked to ß cell dys-
function, is encountered in the 3 types of IEM: intoxica-
tion disorders (mainly haemochromatosis, sometimes
organic aciduria), disorders of energy metabolism
(respiratory chain defects, GSD) or organelle disorders
(Alström and Rogers syndromes, cystinosis). Of these
IEM, iron overload has a special place in adulthood
since hereditary haemochromatosis linked to a mutation
of the HFE 1 gene is one of the most frequent metabolic
diseases, even if its penetrance is variable and is modu-
lated by environmental factors such as body weight and
alcohol.
Dysthyroidism
The IEMs associated with dysthyroidism in adulthood
mainly involve energy metabolism defects and the
degradation or synthesis of complex molecules (Table
3). Primary hypothyroidism is the most frequent feature,
although pituitary participation cannot be excluded in
most cases. Goiter has also been reported. Hyperthyr-
oidism is more questionable. Besides the consequences
of dysthyroidism, hypothyroidism can affect reproduc-
tion and glucose metabolism. When a pregnancy is pos-
sible, preconceptional FT4 and TSH should be assessed,
taking into account the known influence of even subcli-
nical hypothyroidism on early fetal brain development
and long-term cognitive function [42]. Otherwise, overt
hypothyroidism has been associated with increased rates
of spontaneous abortion, premature delivery and/or low
birth weight, fetal distress in labor, and perhaps gesta-
tional hypertension, emphasizing the importance of
thyroid balance before and during pregnancy [43].
Table 3 Main inborn errors of metabolism associated with thyroid dysfunction (Continued)
MCT8 deficiency
Or Allan-Erndon-
Dudley syndrome
Severe cognitive
deficiency,
Hypotonia and
dystonic movement
Progressive spastic
quadriplegia in boys
High serum T3 - low serum rT3
Low serum T4 (sometimes normal)
Normal serum TSH (or slightly elevated)
Nodular dystrophy of the thyroid
Leukocytes MCT8 gene
mutation
(X-linked)
Propylthiouracil and L-
thyroxin
Congenital
disorders of
glycosylation
Affect nearly all
organs and systems
Often, significant
neurological
component.
Most of the time difficulties in TSH
measurement
Always check with a reference method
Rare congenital hypothyroidism
Hypogonadism
N-glycosylation diseases:
serum transferrin
isoelectrofocusing
O-glycosylation disorders:
apo CIII isoelectro-
focusing,
leukocytes DNA
molecular study
Inhibitors of
phosphomannose
isomerase under
evaluation in CDG-Ia
Mannose in CDG-Ib
Selenoprotein
deficiency disorder
Myopathy,
Dermal
photosensitivity
Deficiency of deiodinases: low serum T3 and and
high serum T4
Oligospermia
Leukocytes SECISBP2
gene mutation
Intoxication
disorders
Haemochromatosis Liver, rheumatologic
and heart
involvement
Hypo- and hyperthyroidism: ≤ 1%
Diabetes (10%)Peripheral hypogonadism (5-10%)
Adrenal insufficiency, hypopituitarism, and
hypoparathyroidism: similar to the general
population (except for secondary iron overload)
Transferrin saturation
Serum ferritin
Leukocytes HFE gene
mutation
Phlebotomy
Iron chelation
Abbreviations 3,3’,5-triiodothyronine: T3; 3,3’,5’-triiodothyronine: reverse T3 or rT3; tetraiodothyronine: thyroxine or T4; ATGL or Adipose triglyceride lipase, encoded
by the gene PNPLA2 or patatin-like phospholipase domain containing 2; or alpha/beta-hydrolase domain-containing protein 5, encoded by ABHD5 gene (also
called comparative gene identification-58); AGTX or Alanine-glyoxylate-aminotransferase gene; CDG or congenital disorders of glycosylation; CPK: creatin phospho
kinase; CSF: cerebrospinal fluid; MCT8 (Monocarboxylate Transporter 8) deficiency or Allan-Erndon-Dudley syndrome or SLC16A2-Specific Thyroid Hormone Cell
Transporter Deficiency; SECISBP2 or Sec insertion sequence-binding protein 2 (also known as SBP2)
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DISEASES CLINICAL
MANIFESTATIONS
ENDOCRINE DYSFUNCTION: HYPOGONADISM DIAGNOSIS TREATMENT
Intoxication diseases
Haemochromatosis Melanodermy
Hepatomegaly
Rheumatologic signs
Early heart
involvement in
juvenile forms
Cirrhosis and
hepatocarcinoma
Hypogonadotrophic hypogonadism
- 5%-10% (HFE1)- early-onset in HFE-2 with hear
involvementDiabetes 10%
Hypo- and hyperthyroidism: ≤ 1%
Adrenal insufficiency, hypopituitarism, and
hypoparathyroidism: similar to the general
population (except for secondary iron overload)
Transferrin saturation
Serum ferritin
Leukocytes HFE gene
mutation
Phlebotomy
Iron chelation
Androgen with caution
due to a possible
increased risk of
hepatocarcinoma
Galactosaemia Mental retardation
Cataracts
Osteoporosis
Hypergonadotropic hypogonadism: 75-96% Blood and urine
measurement of
galactose and
galactitol
Leukocytes GALT
gene mutation
Galactose-free diet
Oestrogen from 12-13
years; then + progestins
Discuss recombinant
FSH/oocyte
cryopreservation
Osteoporosis: Calcium ±
vitamin D ±
diphophonates
Complex molecules
disorders
X-linked
adrenoleukodystrophy
Progressive central
and peripheral
nervous system
demyelination
in boys
Clinical hypogonadism: 2/3
Erectile dysfunction: 58%
Small testes: 12%
Primary adrenal failure involving both gluco and
mineralosteroid: 70% in adults
Low
testosterone12%
Inadequate
response to HCG:
88%
High LH:16% and
FSH levels: 32%
High testosterone/
DHT ratio
High VLCFA
Leukocytes ABCD 1
gene mutation
Lorenzo oil
Blood marrow
transplantation
Gene therapy
Perrault syndrome or
D-bifunctional protein
deficiency
Hearing loss
Ataxia
Ovarian dysgenesis Leukocyte HSD17b4
gene mutation,
Sometimes
mitochondrial DNA
mutation
Congenital disorders
of glycosylation
Most are protein
hypoglycosylation
diseases
Affect nearly all
organs and systems
Often a significant
neurological
component.
Hypogonadism with small testes or
amenorrhea
Hypo-, hypergonadotropic or mixed
hypogonadism
Sometimes hyperprolactinaemia
Abnormal TSH
Insulin resistance related to peculiar fat
repartition
N-glycosylation
diseases:
serum transferrin
isoelectrofocusing
O-glycosylation
disorders:
apo CIII
isoelectrofocusing
Leukocytes gene
mutation
Inhibitors of
phosphomannose
isomerase under
evaluation in CDG-Ia
Mannose in CDG-Ib
Cystinosis 3 forms: infantile,
juvenile, ophthalmic
(adulthood)
Liver and muscle
involvement
Progression to end-
stage renal disease
Hypergonadotropic hypogonadism 74% in
males (gonadotropin levels above the normal
range and testosterone levels in the low normal
range); Delayed puberty
Hypothyroidism > 50%
Insulin-dependant diabetes
Growth failure
Gluco-phospho-
aminic diabetes
Hypokalaemia,
acidosis,
Leukocyte cystin
measurement
CTNS gene mutation
Electrolyte
supplementation
Vitamins
Indomethacin
Cysteamine
Fabry disease Acroparaesthesias in
boys
Angiokeratoma
Stroke at young age
Renal, heart and eye
involvement
Hypothyroidism
Isolated case report of subclinical adrenal
insufficiency and hypoparathyroidism
Infertility, osteoporosis
Alpha-galactosidase
A in males
GLA gene mutation
in females (X-linked)
Substitutive recombinant
enzyme therapy
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development, showing the interrelations between the
different hormonal axes [44].
Energy metabolism defects
Mitochondrial cytopathies, especially Kearns-Sayre and
MELAS syndromes, have been reported to be the cause
of primary dysthyroidism in several publications, three
cases of which were autoimmune hyperthyroidism
[8,9,45-48]. Given the frequency of autoimmune dys-
thyroidism in the general population, a fortuitous asso-
ciation between mitochondrial cytopathies and
thyroidopathies cannot be ruled out. Indeed, A3243G
mitochondrial mutation does not actually occur signifi-
cantly more often in patients with autoimmune diseases.
We personally observed one-third of cases with
hypothyroidism, 50% of which displayed a goiter or a
pituitary component in a series of respiratory deficient
patients (unpublished observation). Testing should
always be done for both origins. Thyrotropic insuffi-
ciency is probably underestimated. Energy defects could
impair thyroperoxidase, lowering the production of thyr-
oid hormones, which themselves are involved in mito-
chondrial metabolism, therefore worsening the
mitochondrial dysfunction.
Glycogen storage disease: An increased prevalence of
autoimmune hypothyroidism has been found in type Ib
glycogenosis (glucose-6-phospate translocase defect)
(ORPHA79259); however, patients with the type Ia form
(glucose-6 phosphatase defect) (ORPHA79258) had a
low frequency of thyropathies in a series of patients
with glycogenosis (10 with type 1a and 7 with type Ib)
compared to 34 matched controls [49]. FT4 blood levels
were significantly lower in both type Ia and Ib than in
the control group, whereas TSH, thyroglobulin levels
and antithyroperoxidase antibodies were higher only in
patients with type Ib. Central impairment may be asso-
ciated with these anomalies, since the increase of TSH
level always remains mild. Indeed, glucose-6-phospha-
tase defect inducing glycogen accumulation has been
observed in the pituitary, adrenal, thyroid, parathyroid,
and pancreatic glands. Otherwise, most GSD Ib patients
also show neutropaenia and therefore are at risk of
developing infections and autoimmune-related disorders.
Degradation or synthesis of complex molecules
Fabry disease is an X-linked lysosomal disease related
to an alpha-galactosidase A deficiency, which induces an
accumulation of globotriaosylceramide. Mild forms of
the disorder may appear later in life and affect only the
heart or kidneys. Subclinical, non-autoimmune
hypothyroidism was observed in 4/11 cases in an
untreated series, and in 3 cases associated with adrenal
and gonadal disturbances in another series of 18
patients, 10 of whom were being treated with substitu-
tive enzyme therapy [50,51]. Osteopenia was frequent.
Table 4 Main IEM associated with hypogonadism (Continued)
Alström syndrome Short height
Renal failure
Dilated
myocardiopathy
Blindness, Deafness
Early insulin resistant diabetes - Childhood
obesity
Primary hypogonadism (in males)
PCOS and hirsutism in female
Hypothyroidism
Major
Hypertriglyceridaemia
HypoHDLemia
Leukocytes ALMS I
gene mutation
Selenoprotein
deficiency disorder
Myopathy,
Dermal
photosensitivity
Oligospermia low serum T3 and
and high serum T4
Reduced
selenoprotein
concentrations
Leukocytes SECISBP2
gene mutation
Selenium
supplementation not
efficient on hormone
thyroid profile
Energy defect
Mitochondrial
cytopathies
See Table 2 or 3
Maternal inheritance
Hypogonadotropic hypogonadism: 20% t- 30%
delayed growth and puberty
See Table 2 or 3 See Table 2 or 3
Glycogenosis Liver involvement
Infections in type Ib
Renal complications
in adulthood
Children: fasting ketosis hypoglycaemia; growth
failure
Adults: I, III types: polycystic ovary syndrome,
diabetes, osteoporosis
VI, IX types: spontaneous recovering delayed
puberty
autoimmune hypothyroidism in type I b
hyperlipaemia,
hyperlactataemia,
hyperuricaemia
Leukocytes gene
mutation
Frequent food intake,
uncooked cornstarch
Low carbohydrate
glycaemic index
Night enteral feeding
G-CSF in Ib type,
allopurinol
Avoid oestroprogestative
pills
All autosomal recessive unless otherwise indicated
Abbreviations: DHT: Dihydrotestosterone; G-CSF: Granulocyte colony-stimulating factor; GALT: galactose-1-phosphate uridyltransferase; HSD17B4: 17beta-
hydroxysteroid dehydrogenase type 4 (also known as D-bifunctional protein (DBP). PCOS: Polycystic ovary syndrome; VLCFA: Very long chain fatty acids.
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improve after long-term enzyme replacement therapy
[52].
Cystinosis was complicated by hypothyroidism in 75%
of patients [32-34].
Type 1 hyperoxaluria (< 1-9/1000000,
ORPHA93598) is induced by a liver peroxisomal defi-
ciency secondary to alanine glyoxylate aminotransferase
gene mutations [53]. Several cases of hypothyroidism
revealing or complicating this renal disease have been
reported, without any significance as to the age of the
patient [54,55]. Hypothyroidism is usually severe, prob-
ably linked to the tissular accumulation of calcium oxa-
late, but also to immunoreactivity deficiency and
sensitivity to proteasomal degradation induced by
impaired dimerization in the mutated gene variants.
Neutral lipid storage disease (< 1/1000000,
ORPHA155): This rare non-lysosomal lipid storage dis-
order is caused by defects in two triglyceride-associated
proteins: adipose triglyceride lipase, encoded by the
gene “patatin-like phospholipase domain-containing 2”
(PNPLA2); and “alpha/ß-hydrolase domain-containing
protein 5”,e n c o d e db yt h eABHD5 gene, also called
“comparative gene identification-58”.D y s f u n c t i o no f
these two proteins affects the degradation of triglycer-
ides, and then causes their accumulation in cells with
two different phenotypes [56]. Thyroid nodular dystro-
phy related to intracellular accumulation of triglycerides
has been reported in lipid storage disease with the “ich-
tyosis” phenotype [57] (see Table 3).
MCT8 deficiency: This X-linked mental retardation
syndrome in male subjects involves the transport of
triiodothyronine into neurons with high T3 and inade-
quately low T4 and fT4 concentration [58]. This biologi-
cal effect persists after complete thyroidectomy and
substitution with levothyroxine, which involves periph-
eral deiodination. Progressive thyroid follicular dystro-
phy with a possible risk of papillary carcinoma has been
recently reported [59]. Heterozygous MCT8 women,
usually asymptomatic, should be monitored for the
requirement of L-T4 therapy to prevent fetal and neona-
tal hypothyroidism [58,60]. In families at risk, a prenatal
diagnosis for male fetuses can be done. Treatment with
propylthiouracile and L-thyroxine has been proposed
[61].
Congenital disorder of glycosylation: Thyroid func-
tion tests are frequently abnormal in children with
CDG; congenital hypothyroidism has been suspected.
However, free thyroxine analyzed by equilibrium dialy-
sis, the most accurate method, was reported as normal
in seven individuals with CDG [62]. In contrast, CDG
are associated with hypogonadism and are detailed in
this section.
Selenoprotein deficiency disorder (ORPHA209193):
Selenium is a micronutrient involved in selenoprotein
metabolism, such as the glutathione peroxidase, mediat-
ing the removal of cellular reactive oxygen species, and
deiodinases, which are involved in thyroxine metabo-
lism. Mutations in the SECISBP2 (Sec insertion
sequence-binding protein 2, also known as SBP2) gene
result in reduced synthesis of all selenoproteins, and
have a multisystem expression with an abnormal thyroid
hormone profile (low T3, high T4) [63,64]. Selenium
supplementation fails to correct the selenoprotein synth-
esis defect in subjects with SBP2 gene mutations [65].
Haemochromatosis: A case of a 56-year-old male
patient with haemochromatosis complicated by cirrhosis,
insulin-dependent diabetes and hypogonadism with
regressive hypothyroidism after venopuncture has
recently been reported [66]. Nevertheless, in two studies
of 100 to 200 homozygote C282Y patients, the preva-
lence of hypo- and hyperthyroidism that was below 1%
did not differ from that of the control group [67]. Dys-
thyroidism was however more frequent in acquired
haemochromatosis.
In conclusion, dysthyroidism may complicate energy
metabolism diseases (respiratory chain defect, GSD) or
organelle disorders affecting mainly the kidney (cystino-
sis, type I hyperoxaluria) or selectively the thyroid gland
(MCT8 and selenoprotein deficiencies).
Hypogonadism
Medical advances have enabled the survival of patients
suffering from IEM. Nevertheless, hypogonadism
remains one of the most frequent complications in ado-
lescence. Optimization of pubertal progress should
reduce the impact of growth retardation, later adult
bone loss and related psychosocial issues. Screening for
primary or hypogonadotrophic hypogonadism, as well as
osteoporosis, should be done in adulthood.
Intoxication disorders
Haemochromatosis: Hypogonadotropic hypogonadism
was found in 5.2% of a series of 38 female patients and
6.4% of a series of 141 male subjects, 89% of whom also
had cirrhosis and 33% diabetes [68]. This prevalence of
hypogonadism had been previously evaluated at 40%,
with this fact being linked to an earlier diagnosis and
treatment. In another series of 87 patients with heredi-
tary hemochromatosis, osteoporosis was detected in 25%
and osteopenia in 41%. Bone mineral density was inde-
pendently associated with body mass index, hypogonad-
ism/menopause, and the amount of iron removed to
reach depletion [69]. Furthermore, haemochromatosis
should always be suspected in male subjects with iso-
lated hypogonadotropic hypogonadism. In young men,
Vantyghem et al. Orphanet Journal of Rare Diseases 2012, 7:11
http://www.ojrd.com/content/7/1/11
Page 12 of 19the diagnosis of juvenile haemochromatosis, despite its
rarity, should be considered, especially in case of cardiac
involvement. At least three Japanese men bearing new
mutations of the HJV (hemojuveline) gene, which is
usually found in so-called “juvenile” haemochromatosis,
were diagnosed in their fifties due to hypogonadism,
showing the wide variability of the phenotype [70].
Pituitary iron overload, as well as the HFE and transfer-
rin genotype, may explain the hypothalamic-pituitary-
gonadal involvement [71]. If diagnosed early, hypogo-
nadism can regress after phlebotomy. The treatment
with androgens might be difficult considering the
increased risk of hepatocarcinoma when associated with
cirrhosis and the potential carcinogenic role of androgen
therapy [72].
Classical galactosemia is a not so rare disorder of
galactose metabolism. Despite a strict diet and newborn
screening, long-term complications usually include men-
tal retardation, cataracts and ovarian insufficiency in
most girls [73]. Indeed, in a series of 34 female patients
aged 17 to 51 years, only 4 menstruated regularly with-
out any treatment, and a single pregnancy occurred
spontaneously [74]. In another series of 33 patients (16
women), all female subjects had ovarian insufficiency.
One woman and two men had children. The genotype
does not seem to predict the chances of becoming preg-
nant [73,74]. During pregnancy, elevations in galactose
metabolites do occur but without evidence of clinical
impact on the mother or child, although possible long-
term effects have not been thoroughly investigated [75].
Many mechanisms are involved including: 1) an accu-
mulation of galactose-1-phosphate, which induces a
rapid loss of follicles through cellular apoptosis, and of
galactitol, which alters the ovarian tissue; and 2) a defi-
ciency in UDP-galactose, which alters glycosylation, pos-
sibly impairing FSH activity [76-79]. Hypoglycosylation
is diet-dependent and may worsen when galactose
intake increases either because of poor compliance or
unrestricted diet.
Currently, haemochromatosis and galactosemia are
the two main intoxication diseases that are complicated
by hypogonadism. In contrast with iron overload, in
which hypogonadism can be prevented or improved
through treatment, hypogonadism in female patients
with galactosemia is a unique endocrine complication
and occurs in most patients despite early prospective
treatment.
Organelle disorders involving the synthesis or
degradation of complex molecules
X-Adrenoleukodystrophy (X-ALD) and D-bifunctional
protein (D-BF) deficiency (ORPHA300): X-ALD is a
progressive peroxisomal disorder affecting adrenal
glands, testes and myelin stability caused by mutations
in the ABCD1 gene, which encodes for ALD protein.
The anomalies of this peroxisomal transporter induce a
ß-oxidation defect of VLCFA [80,81]. X-ALD is asso-
ciated in more than two-thirds of cases with clinical
hypogonadism and anomalies of the gonadotropic axis
[82]. Severe impairment of spermatogenesis and rapid
progression to azoospermia were reported despite nor-
malization of plasma VLCFA concentrations in a post-
pubertal patient [83]. Oxidative stress plays a role, at
least in the neurodegeneration features [84]. Otherwise,
although D-BF protein deficiency is in general a severe
neonatal or infantile disease mimicking the peroxisome
biogenesis or so-called Zellweger spectrum disorders
[85,86], two siblings with Perrault syndrome were
reported with mutations in the D-BP (HSD17b4) gene
[87]. However, other patients with Perrault syndrome
had no mutations in this gene, indicating that this syn-
drome is genetically heterogeneous and is sometimes
related to mutations of mitochondrial DNA [88].
Congenital disorders of glycosylation (CDG) are a
rapidly growing group of diseases that impair protein
glycosylation, one of the major functions occurring in
the endoplasmic reticulum and Golgi compartments
[89]. The clinical manifestations are heterogeneous
[90,91]. Elevated tissue fibrosis, frequent in CDG
patients, could promote hypogonadism, which is fre-
quent, especially in males [92-97]. Varying hormonal
profiles and degrees of virilization in CDG females sug-
gest a spectrum of yet unidentified mechanisms affected
by impaired N-glycosylation [98]. Potential treatment of
the most common form, CDG-Ia, with phosphomannose
isomerase inhibitors is under evaluation [99].
Cystinosis: The onset of puberty was consistently
delayed in a series of 17 patients with chronic renal
insufficiency [100]. Hypergonadotropic hypogonadism
has been found in 50% to 75% of males. It seems to be
related to fibrosis and testicular atrophy and promotes
growth retardation [33,34,100].
Fabry disease: 89% of women may have menstrual
disorders (or spontaneous abortions), although gonado-
tropic stimulation tests were normal in women; oligo/
asthenozoospermia is frequently found in males
[51,101].
Alström disease: The most common endocrinological
manifestation besides type 2 diabetes is hypogonadism. In
a series of 182 patients (83 males) [28], hypergonadotropic
and hypogonadotropic hypogonadism were common in
males (77%). Puberty was often delayed, but masculiniza-
tion and secondary sexual characteristics in adult males
were normal. Basal testosterone levels were frequently
diminished for age with increased baseline luteinizing hor-
mone/follicle-stimulating hormone levels typical of pri-
mary gonadal failure. Gynecomastia was present in 37% of
males, as was cryptorchidism in 0.02% of cases. The mean
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were observed in 54% of 78 females and included hirsut-
ism, abnormal breast development, cystic ovaries, preco-
cious puberty (pubertal onset at age < 8 years),
endometriosis, irregular menses and amenorrhea.
Finally, peroxysomal, lysosomal and reticulum endo-
plasmal disorders are frequently associated with mani-
festations such as delayed onset of puberty,
hypogonadism and infertility, as well as other endocrine
disorders. Their responsiveness to treatment has not
been fully investigated up till now.
Energy metabolism disorders
Mitochondrial cytopathies: Hyper- [88,102] and hypo-
gonadotropic [9,103-105] hypogonadism have been
described in case reports [106], but the frequency can
reach 20% in patients with Kearns-Sayre syndrome [45].
Anomalies of estrogen metabolism in the muscle have
also been reported in these patients who often have a
myopathic component [107,108].
In a series with glycogen storage disease, both type I
(n = 13) and type III (n = 14), all patients older than 4.8
years presented with polycystic ovary syndrome but
without hormonal biological disturbances, except hyper-
insulinaemia [109]. Delayed puberty-related growth
impairment and short stature have also been described.
The role of glucose metabolism alteration is probably
involved in the ovarian pathophysiology.
Finally, hypogonadism is a less frequent complication
of energy metabolism disorders than of organelle
disorders.
In conclusion with regard to hypogonadism,m o s t
IEMs can be complicated by hypogonadism, but classical
galactosemia and organelle disorders are the most fre-
quently involved diseases. Except for iron overload, in
which hypogonadism might be prevented or improved
with iron depletion, the mechanisms are not yet fully
understood and causal treatment remains difficult.
Adrenal failure
As with thyroid hormones, steroids are liposoluble hor-
mones, and adrenal insufficiency has mainly been
reported in adrenoleukodystrophy (X-ALD) and energy
metabolism defects.
X-adrenoleukodystrophy, the most common cause of
primary adrenal failure in IEM, is associated with neuro-
logical symptoms [80,81]. In adulthood, adrenal insuffi-
ciency, which generally appears after the age of 3-4
years, is present in 70% of patients. It can be the first
and only manifestation of the disease for decades. Its
association with neuropathy suggests the diagnosis. At
age 20 years, it is usually associated with hypergonado-
tropic hypogonadism.
Fabry disease: Patients with Fabry disease have been
found to have lower mean cortisol plasma levels than in
controls. Partial adrenal insufficiency was observed after
the ß1-24 corticotrophin test in only one of the 18 stu-
died patients [51]. These data need to be confirmed
since acute adrenal failure has never been reported
before.
Niemann-Pick disease (< 1-9/100000, ORPHA645)
is a lysosomal lipid storage disease caused by mutations
in the sphingomyelin phosphodiesterase 1 (SMPD1) gene,
which results in the deficient activity of lysosomal acid.
Partial adrenal insufficiency has been reported in type B,
a non-neurologic, visceral form with hepatosplenome-
galy, pulmonary disease and survival into adolescence
and/or adulthood [110].
Mitochondrial cytopathies: Adrenal failure is rare in
childhood but might reveal the presence of the disease
[111], thus being a poor prognostic factor [112-114]. In
adulthood, subclinical adrenocortical insufficiency is
sometimes found in multisystemic forms [115]. Various
types of aldosterone secretion disturbances, mainly sec-
ondary hyperaldosteronism possibly linked to tubulopa-
thies, have also been reported [45,116].
Hypoparathyroidism
Hypoparathyroidism may occur, though rarely, in all
types of IEM, the most frequent being mitochondrial
cytopathies [117-119].
Hypoparathyroidism might also complicate acquired
iron overload in major thalassemia [120], and occa-
sionally adrenoleukodystrophy, and Fabry or Wilson’s
disease (< 1-9/100000, ORPHA905), a congenital dis-
order of copper metabolism affecting the hepatic and
nervous systems [121,122].
In fatty acid oxidation (FAO) disorders, and particu-
larly in LCHAD (long-chain 3-hydroxyacyl-coenzyme A
dehydrogenase) deficiency (< 1-9/100000, ORPHA5) and
trifunctional enzyme defects, which are characterized by
neuropathy and retinopathy, transient hypoparathyroid-
ism occurs frequently in cases of acute decompensation
and is usually asymptomatic [123,124]. Later-onset exer-
cise-induced myopathic symptoms remain characteristic
clinical features of FAO disorders, in addition to heart
and liver involvement.
Hypopituitarism and growth
Pituitary assessment has not been systematically done in
IEM. Relative problems could go partially unrecognized
due to the difficulty of the evaluation in subclinical
forms and the possible mixed primary and pituitary
involvement. Otherwise short stature might also be mul-
tifactorial due to liver or renal dysfunction, poor nutri-
tional status or psychosocial issues.
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dus [19] have been reported in mitochondrial cytopa-
thies [9,45,103,104] and iron overload [125-127].
Growth retardation was found in 30% to 60% of
mitochondrial cytopathies, cystinosis [34] and galactose-
mia [128]. The resulting short stature is also found in
Niemann-Pick disease [110] and Alström syndrome [28].
However, Alström syndrome is associated with
advanced bone age, and normal early growth may be
due to hyperinsulinism [28,129,130], although in a series
of 15 patients, no significant relation was observed
between IGF (Insulin Growth Factor) levels and body
mass index or blood glucose, insulin and testosterone
levels [131]. Type 1 hyperoxaluria is also associated with
advanced skeletal age in young patients, increased
FGF23 (Fibroblast Growth Factor 23) levels and
decreased bone mineral density, thus promoting frac-
tures [132]. Further investigations, including GH
(Growth Hormone) dynamics, are needed to determine
whether disturbances in the GH/IGF axis contribute to
this relatively short stature, the origin of which is prob-
ably multifactorial through decreased renal function,
feeding difficulties, hypothyroidism, hypogonadism, etc.
Conclusion
With the exception of iron overload, IEM are very rare
disorders. They may be associated with endocrine disor-
ders, most of which are linked to carbohydrate metabo-
lism disturbances, thyroid dysfunction and
hypogonadism. The endocrinologist may screen patients
with a diagnosis that was established in childhood for
complications. In rarer cases, the diagnosis of IEM
should be suspected when there are multiple endocrino-
pathies or when there is associated multisystemic injury.
A prospective investigation of endocrine function should
probably be scheduled in IEM, since numerous asymp-
tomatic endocrine disorders with delayed manifestations
have been found. Indeed, the long-term consequences of
IEM on fertility and bone are still poorly understood.
Mechanisms such as energy required for hormonal
synthesis, toxic accumulation of a metabolite, hormone
transportation defect or hormone/receptor glycosylation
should be better investigated in order to improve our
understanding of the pathophysiology and to help inno-
vate in the screening and treatment of endocrine disor-
ders. A few biological exams relying on baseline blood
and urine sampling can steer the diagnosis. Consultation
with a specialist is usually required in reference centers,
with whom it is often necessary to collaborate.
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